GRIA2 and myeloid sarcoma: In patients with more severe ischemic clinical events, grouped as a transient ischemic attack (TIA) and minor stroke (MS), the mean expression level of AMPA-type glutamate receptors GRIA1 and GRIA2 was lower than in individuals with less severe adverse vascular symptoms (amaurosis fugax, AF) or without reported symptoms.